Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
03/23 NEW CHROMATOGRAPHY STUDY FINDINGS HA : A Pitfall Associated...
03/23 ASTELLAS PHARMA : Findings from Astellas Pharma Provide New Insights into Urothe..
03/23 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
03/23 CYTOKINETICS : Announces Preclinical Data for CK-2127107 Presented at MDA Scient..
03/23 ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 189KB)
03/22 ASTELLAS PHARMA : Launch of LINZESS® Tablets 0.25mg in Japan
03/16 ASTELLAS PHARMA : Researchers from Astellas Pharma Discuss Findings in Liver Can..
03/13 ASTELLAS PHARMA : Work begins on new pneumococcus vaccine
03/09 ASTELLAS PHARMA : Study Findings on Anemia Are Outlined in Reports from Astellas..
02/28 ASTELLAS PHARMA : and Affinivax Announce Worldwide Partnership for MAPS Vaccine ..
More news
Sector news : Pharmaceuticals - NEC
11:08pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
11:05pDJSHIRE : Files 8K - Other Events
07:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- Update
06:51pDJSenator McCaskill Begins Probe of Prescription Opioid Marketing
06:27pDJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/10 More Lost Than Gained In Shifting R&D Forecasts
02/10 ASTELLAS PHARMA : A Contrarian Investment
02/03 Pfizer May Be Another IBM
02/02 Astellas Pharma Recommended By Charles De Vaulx Of IVA Funds
01/31 Astellas Pharma reports 9M results
Advertisement
Financials ( JPY)
Sales 2017 1 321 572 M
EBIT 2017 275 000 M
Net income 2017 204 061 M
Finance 2017 465 287 M
Yield 2017 2,30%
P/E ratio 2017 15,32
P/E ratio 2018 14,88
EV / Sales 2017 2,09x
EV / Sales 2018 1,93x
Capitalization 3 230 735 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 1 815  JPY
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-6.95%29 193
JOHNSON & JOHNSON8.91%341 030
ROCHE HOLDING LTD.8.73%220 248
PFIZER INC.5.23%203 546
NOVARTIS AG-0.47%195 735
MERCK & CO., INC.7.34%173 493
More Results